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Abstract 
Background: Despite a dearth of knowledge on the causes of prescribing errors in medical
practice, and the rates of prescribing errors among certain patient groups, little Irish research
exists to address this issue. One possible reason for this is that the analysis of prescription
modification is not part of the recognised job description of a pharmacist.
Aims: To investigate the prevalence, nature and risk factors for prescription modifications in
an Irish community pharmacy.
Methods: A cross-sectional study was performed to examine prescriptions dispensed in an
Irish community pharmacy over a period of five weeks.
Results: In total, 866 prescriptions were examined. The overall prevalence of prescribing
errors and prescription modifications was 17.9% (155), with a mean of 31 modifications per
week. Prescription only medicines (POM) comprised 94.8% (147) of the modifications, of
which 87% (128/147) were prescription errors requiring a simple clerical clarification before
dispensing could occur. The remaining 13% (19; average of 3.8 per week) were prescribing
faults with potential clinical consequences if left unaltered. Half (51%) of all POM
modifications occurred through consultation with the patient or their representative. The
following factors were associated with increased risk of POM modifications: being a female
patient (OR=1.605, 95% CI 1.104-2.333, p=0.013); and, being prescribed drugs in the
following therapeutic areas – musculoskeletal (OR=1.906, 95% CI 1.023-3.551, p=0.042),
and genitourinary system and sex hormones (OR=3.691, 95% CI 2.255-6.042, p<0.001).
Subsequent multivariate analysis confirmed these as significant independent risk factors for
POM modifications.
Conclusions: The majority of prescribing errors modified involved non-serious clerical errors.
However, an average of 3.8 POM prescriptions with potential clinical consequences were
modified weekly.
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Introduction
Medicines should be prescribed only when they are necessary, and
in all cases the benefit of administering the medicine should be
considered in relation to the risk involved; these guidelines are
stated in the British National Formulary, as well as being common
sense to practitioners.1 Even so, large-scale studies in the US2 and
the UK3 by the Institute of Medicine (IOM) and the UK General
Medical Council (GMC), respectively, have shown that medication
errors, the most common of which are prescribing errors,4 are
common in practice. Jeffrey Aronson, a clinical pharmacologist
based in Oxford University, devised a method for classifying
incorrect prescriptions as either faults or errors based on
psychological theory. Aronson’s definitions aim to explain errors
rather than merely describing them.5
Prescribing faults concern the decision-making process in writing a
prescription (e.g., dose too high or low, or drug allergy or
contraindication), while prescription errors concern the act of
writing the prescription (e.g., absence of drug strength or number
of tablets).5 Prescription modifications, on the other hand, are
interventions that prevent error occurrence and can be made
through contact with the doctor about a query, checking the
patient’s medication history, or interviewing the patient or their
representative.6 They are required when there is a reduction in the
probability of treatment being timely and effective, or an increase in
the risk of harm to the patient when compared to generally
accepted practice.7
The 2012 PRACtICe study carried out by the GMC found that one in
20 prescriptions contained a prescribing or monitoring error,
affecting one in eight patients, with severe errors (a score greater
than 7 on a scale numbered from zero to 10) found in one in 550
prescription items.3 Another UK study, the 2009 EQUIP study,
looked at the causes of prescribing errors by foundation trainee
doctors, and reported a mean of 8.9 errors per 100 medication
orders.8 These proportions may be even higher in Ireland. In 2013,
more than 20 million prescriptions were filled in Ireland for over 60
million medical items, including medicines and medical devices.9 In
2009, Sayers et al. found that 12.4% (491) of the prescriptions
written by 28 general practitioners in Galway and Donegal
contained one or more prescribing errors.10 Much of the Irish
research available has concentrated on the incidence or prevalence
of prescribing errors. Several of these have focused on errors more
common in specific patient groups (e.g., patients over 65 years) or
in certain therapeutic classes of drugs.11,12,13,14 There is, however, a
gap in the literature with regard to studies that simultaneously take
into account patient-, drug- and prescriber-related factors that
contribute to prescription modifications as a result of prescribing
errors. 
Large-scale studies have been conducted in the US, the Netherlands
and the UK to assess community pharmacy interventions intended
to reduce prescribing errors, but data in this field is lacking thus far
in Ireland.6,15,16 Such research will provide a fuller picture of the
risk factors for prescribing errors and prescription modifications in
an Irish context, which may lead to new strategies aimed at
reduction.
Methods
Study design
A cross-sectional study was performed to examine prescriptions
dispensed in a community pharmacy in Leinster over a period
of five weeks in winter 2012. All prescriptions were included
and each was checked for prescribing errors by the supervising
pharmacist. This included medications, as well as other
healthcare products such as diabetes test strips, bandages, and
needles. Inclusion criteria were based on the need for
prescription modification.7 The following were excluded from
modification because of their lack of potential impact on
patient care: address incorrect or absent; medical scheme data
incorrect or absent; incorrect package size; product not in
stock; unit of dosage or package specified incorrectly (e.g., mL
instead of g); generic substitution; or, legal prescription
requirements (e.g., for controlled drugs). Where there were two
or more reasons given for a modification, the most relevant
reason was selected based on the highest risk of harm to the
patient.
Classification of prescription items
Prescribed items were classified according to guidelines set out
in the Irish Medicinal Products Regulations, as prescription only
medicines (POM), over-the -ounter medicines (OTC) or
non-medicines. All medicines were classified into therapeutic
groups using the Anatomical Therapeutic Chemical (ATC)
classification given by the WHO Collaborating Centre for Drug
Statistics Methodology.17 During the data management process,
prescribing errors were divided into two groups as per Aronson:
prescription errors and prescribing faults.5
Data collection and analysis
Data collected from eligible prescriptions included: the date the
prescription in question was dispensed by the pharmacy; the
therapeutic group of the prescribed drug; the age and gender
of the patient; a description of the nature of the prescription
(printed or handwritten, POM, OTC medicine or non-medicine);
a description of the prescriber (the patient’s own GP or another
physician); and, a description of the modification type, if any
was made. 
Descriptive statistics were used to determine the prevalence of
POM modifications, and logistic regression was used to estimate
the association between prescription characteristics and
modification. Multivariate logistic analysis was then performed
combining the significant univariate predictors, to determine
their independence or otherwise.
Results
Descriptive statistics
Over the five-week study period, 1,303 prescriptions were
collected by the pharmacy and 66% (866) were analysed.
Those excluded were collected on the days the supervising
pharmacist was absent. Of the 866 prescriptions included,
17.8% (155) were modified, 94.8% (147) of which were due to
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POMs. The mean age of patients whose prescriptions required
modification was 40.15 years and the majority were women
(63.9%). Printed prescriptions accounted for 64.5% (100),
while prescriptions written by the patient’s own doctor or
prescriber accounted for 85.8% (133) (Table 1).
Nature of prescription modifications
The numbers of modified OTC (3.9%) and non-medicine
prescriptions (1.3%) were too small for statistical analysis; as such,
only POM modifications were considered further. POM
modifications occurred with greater frequency in the following
therapeutic classes: nervous system (ATC code N); anti-infectives
for systemic use (ATC code J); genitourinary system and sex
hormones (ATC code G); respiratory system (ATC code R);
dermatologicals (ATC code D); and, musculoskeletal system (ATC
code M) (Figure 1). The majority (87%; 128) of the POM
modifications concerned a prescription error where clarification of
an insufficiently written prescription was needed (e.g., omitted
drug dose), while the other 13% (19) were prescribing faults (e.g.,
dose too high). POM modifications after consultation with a
patient or proxy, where the pharmacist identified a need for
clarity, accounted for the greatest number of interventions. In 51%
(75) of cases, the pharmacy consulted the patient or their proxy,
either to clarify the doctor’s intentions or to establish their
knowledge or need for additional medicines information. In 30%
of cases (44), modifications of POM prescriptions were made after
consultation with the prescriber or the prescriber’s assistant. These
included instances where a drug was either out of stock or
unavailable in Ireland, or where the strength or dose of a medicine
was omitted. The remaining 19% (28) were made based on the
patient’s medical history (e.g., where a contraindication/allergy
was present).
                                       ATC class nervous system
              ATC class anti-infectives for systemic use
ATC class genitourinary system and sex hormones
                                  ATC class respiratory system
                                       ATC class dermatologicals
                                                    Other ATC classes
                           ATC class musculoskeletal system
Table 1: Analysis of prescriptions.
                                                                                             All                                                  Modified                                             Non-modified
                                                                                     prescriptions                                       prescriptions                                           prescriptions
                                                                                         (n=866)                                         n (%) (n=155)                                        n (%) (n=711)
Drug-related factors
Prescription only medicine (POM)                                   796 (92%)                                         147 (94.8%)                                            649 (91.2%)
Over-the-counter medicine (OTC)                                   42 (4.8%)                                             6 (3.9%)                                                 36 (5.1%)
Non-medicine                                                                  28 (3.2%)                                             2 (1.3%)                                                 26 (3.7%)
Patient-related factors
Age, mean (SD)                                                             43.01 (21.9)                                       40.15 (22.82)                                           43.64 (21.71)
Female                                                                           490 (56.6%)                                         99 (63.9%)                                               391 (55%)
Prescriber-related factors
Handwritten prescriptions                                              263 (30.4%)                                         55 (35.5%)                                             208 (29.2%)
Own doctor/prescriber                                                   725 (83.7%)                                        133 (85.8%)                                            592 (83.3%)
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FIGURE 1: Therapeutic classes where POM modifications occurred with greater frequency.
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Univariate and multivariate risk factors for prescription modification
Univariate analysis identified two therapeutic drug classes that
exhibited significantly higher rates of POM modifications: the
genito-urinary system and sex hormones therapeutic drug class
(ATC code G), where modifications were almost three times more
likely than in other therapeutic classes (OR=3.691, 95% CI
[2.255-6.042], p<0.001), and the musculoskeletal system
therapeutic class (ATC code M) (OR=1.906, 95% CI [1.023-3.551],
p=0.042) (Table 2). 
Gender was also found to be a significant risk factor for POM
modifications, with female patients significantly more likely to have
their prescriptions modified (OR=1.605, 95% CI [1.104-2.333],
p=0.013) than male patients. Multivariate analysis showed that
these remained strong independent risk factors for POM
modifications. Prescriber-related factors such as handwritten or
typed prescriptions and the source of the prescription (patient’s own
doctor/other prescriber) were not significant. This result was unusual
but not unexpected, as low numbers of patients (16.2%; 141 of
866) in this study utilised a doctor or prescriber other than their
own. Patient’s age was also not significant.
Discussion
In this study, the overall prevalence of prescription modifications
was 17.9%. As a measure of modification rate this is very high,
especially when compared to results reported in similar studies
performed in the US, the Netherlands by Buurma et al., and the UK.
These reported modification rates of 3.8% (102) from 2,690
prescriptions, 4.3% (2014) from 47,374 prescriptions, and 0.75%
(1,500) from 201,000 prescribed medical items, respectively.6,15,16
Differences in national healthcare programmes – for example the
use of electronic prescribing, which has been associated with much
lower error rates than handwritten prescriptions18 – in the US, the
UK and the Netherlands, may partly account for this difference in
modification rates. In this study, there were far fewer modifications
of prescribing faults than there were of prescription errors, meaning
that the majority of modifications were of errors that were unlikely
to cause patient harm. There was a 2.2% (19 of 866) modification
rate when it came to these prescribing faults, representing a mean
of 3.8 POM prescribing faults in the pharmacy per week. In
contrast, there was a 14.8% modification rate for prescription
errors, a mean of 25.6 POM prescription errors in the pharmacy per
week.
Drugs from the nervous system therapeutic class made up the
highest source of POM modifications in this study, which is
consistent with previous studies such as Buurma et al.15 However,
these results differ with regard to finding significant associations
between drugs in both the genitourinary system and sex hormones
therapeutic drug class and POM modifications. Our findings
regarding drugs in the genitourinary system and sex hormones
therapeutic class (ATC code G) were unexpected, as our literature
review did not flag this drug class. It is important to mention that
the majority of modifications for this drug class concerned
clarifications about directions for use, where they were either
missing or incomplete. 
One possible reason for the incompleteness of the dose directions
may be due to patients being already familiar with how to use their
medicines. In this regard, individual experience about what
constitutes a prescribing error may also have had consequences on
error detection in this study.
There was also a significant association between POM modifications
and female gender. This was at odds with our literature review,
where associations between gender and prescribing errors were
either insignificant15 or found to be higher in male patients.3,19 A
number of factors may account for this finding; for example, all
concerned drugs in the genitourinary system and sex hormones
therapeutic drug class in this study were oral contraceptives.
However, multivariate analysis shows both gender and drugs with
ATC code G to be independent variables. 
Table 2: Univariate and multivariate risk factors for prescription modification.
                                                                                       Univariate                                                                                       Multivariate
                                                          Modified POM        Odds              95% I            p value                 Modified POM      Odds             95% I             p value
                                                            prescriptions          ratio                (df)                                             prescriptions         ratio               (df)
                                                          (n=147, 100%)        (OR)                                                                (n=147, 100%)       (OR)
Drug related factors
ATC-code N                                           37 (25.2%)           1.098         0.762-1.578         0.619
ATC-code J                                             32 (21.8%)           1.033         0.701-1.523         0.870                               
ATC-code G                                           24 (16.3%)           3.691         2.255-6.042        <0.001                     24 (16.3%)          3.531        2.095-5.952        <0.001
ATC-code R                                            17 (11.6%)           1.463         0.932-2.298         0.098
ATC-code D                                            14 (9.5%)            1.169         0.646-2.116         0.606
ATC-code M                                            10 (6.8%)            1.906         1.023-3.551         0.042                       10 (6.8%)           2.408        1.248-4.645         0.009
Patient-related factors
Age, mean (SD) (n=139)                        39.6 (22.4)           0.993         0.985-1.001         0.081
Female                                                   99 (67.3%)           1.605         1.104-2.333         0.013                      99 (67.3%)          1.595        1.073-2.372         0.021
Prescriber-related factors
Handwritten                                           50 (34.0%)           1.247         0.855-1.818         0.253
Own doctor/prescriber                          125 (85.1%)          1.142         0.697-1.872         0.598
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We found that printed prescriptions had a reduced frequency of errors,
consistent with results by Buurma et al.15 Most of our (51%) POM
modifications were made based on consultation with the patient or
their proxy. In contrast, Warholak and Rupp reported that the majority
(64.1%) of their modifications were made based on consultation with
the prescriber.6 The biggest limitation in this research was regarding
study design. As the research was cross-sectional, causality could not be
inferred. Also, our study was conducted in just one pharmacy and may
not be generalisable to others. We found a mean prescribing error rate
of 17.9 errors per 100 prescriptions, corresponding to an average of 31
prescribing errors per week; a comparatively higher rate than that
reported in the GMC PRACtICe study and the EQUIP study,3,8 but
within the range (12.4-27%) that has been reported across various
healthcare settings in Ireland.10,11,20
Conclusion
The majority of prescribing errors modified in this study involved
non-serious clerical errors. However, an average of 3.8 POM
prescriptions with potential clinical consequences were modified
weekly. Most were resolved through consultation with the patient or
their representative, or checking the patient’s medical history, more so
than through contact with the doctor or the prescriber.
This study is important because it is the first Irish article that shines a
light on the little-acknowledged phenomenon of prescription
modification. Patient factors like female gender, as well drug factors
such as the therapeutic class of drugs (e.g., genitourinary and sex
hormones therapeutic class and musculoskeletal therapeutic class) have
implications for the probability of prescription modifications, which
suggests that focus must be put on ways to mitigate errors arising from
patients and prescriptions that fit that profile.
Pharmacists and community pharmacies play a pivotal role in
preventing prescribing errors. This study also illustrates the critical role
that patient involvement can play in the prescribing process with
regard to harm prevention and improved compliance. Future research
should build upon this study and explore modification boundaries that
should be removed or installed to advance patient safety.
